Friday, February 28, 2014 9:21:19 PM
CONCLUSION
The early stage biotech industry is tough for shareholders under the best circumstances. Well-funded companies staffed with honest and legitimate scientists putting shareholder value first, still fail constantly. NNVC has burned ~$33m in cash over the past nearly 7+ years and done essentially nothing as far as we can tell except dilute public shareholders, make insiders rich and develop Anil Diwan's technology.
Even if you believe NNVC has legitimate technology with the best management team, who you believe will put your shareholder interests ahead of your own, NNVC valuation still makes zero sense. With 10k+ publicly traded companies and thousands of life sciences companies, we cannot imagine why anyone is unable to find something better to do with their money than "invest" it in this worthless shell where shareholders own virtually nothing and management seems intent on extracting all the money for themselves. NNVC is clearly held together with scotch tape and we recommend investors sell their shares immediately before this house of cards comes crashing down.
http://seekingalpha.com/article/2010691-nanoviricides-house-of-cards-with-minus-80-percent-downside-strong-sell-recommendation
The early stage biotech industry is tough for shareholders under the best circumstances. Well-funded companies staffed with honest and legitimate scientists putting shareholder value first, still fail constantly. NNVC has burned ~$33m in cash over the past nearly 7+ years and done essentially nothing as far as we can tell except dilute public shareholders, make insiders rich and develop Anil Diwan's technology.
Even if you believe NNVC has legitimate technology with the best management team, who you believe will put your shareholder interests ahead of your own, NNVC valuation still makes zero sense. With 10k+ publicly traded companies and thousands of life sciences companies, we cannot imagine why anyone is unable to find something better to do with their money than "invest" it in this worthless shell where shareholders own virtually nothing and management seems intent on extracting all the money for themselves. NNVC is clearly held together with scotch tape and we recommend investors sell their shares immediately before this house of cards comes crashing down.
http://seekingalpha.com/article/2010691-nanoviricides-house-of-cards-with-minus-80-percent-downside-strong-sell-recommendation
The SwingTrade Portfolio was up 83.5% in 2013 and 348.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95479424
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
